S. Cosgrove, G. Sakoulas, E. Perencevich, M. Schwaber, A. Karchmer et al., Bacteremia: A Meta???analysis, Clinical Infectious Diseases, vol.36, issue.1, pp.53-59, 2003.
DOI : 10.1086/345476

P. Zarb, B. Coignard, and J. Griskeviciene, The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use, Euro Surveill. Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull, vol.17, 2012.

S. Grau, E. Fondevilla, and N. Freixas, Relationship between consumption of MRSA-active antibiotics and burden of MRSA in acute care hospitals in Catalonia, Spain, Journal of Antimicrobial Chemotherapy, 2014.
DOI : 10.1093/jac/dku487

S. Hawser, S. Bouchillon, D. Hoban, M. Dowzicky, and T. Babinchak, Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004???2009, International Journal of Antimicrobial Agents, vol.37, issue.3, pp.219-224, 2004.
DOI : 10.1016/j.ijantimicag.2010.10.029

S. Tsiodras, H. Gold, and G. Sakoulas, Linezolid resistance in a clinical isolate of Staphylococcus aureus, The Lancet, vol.358, issue.9277, pp.207-208, 2001.
DOI : 10.1016/S0140-6736(01)05410-1

A. Gales, H. Sader, S. Andrade, L. Lutz, A. Machado et al., Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis, International Journal of Antimicrobial Agents, vol.27, issue.4, pp.300-302, 2006.
DOI : 10.1016/j.ijantimicag.2005.11.008

E. Ramírez, R. Gómez-gil, and A. Borobia, Improving linezolid use decreases the incidence of resistance among Gram-positive microorganisms, International Journal of Antimicrobial Agents, vol.41, issue.2, pp.174-178, 2013.
DOI : 10.1016/j.ijantimicag.2012.10.017

H. Quan, V. Sundararajan, and P. Halfon, Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data, Medical Care, vol.43, issue.11, pp.1130-1139, 2005.
DOI : 10.1097/01.mlr.0000182534.19832.83

C. Liu, A. Bayer, and S. Cosgrove, Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children, Clinical Infectious Diseases, vol.52, issue.3, pp.18-55, 2011.
DOI : 10.1093/cid/ciq146

J. Garau, E. Bouza, J. Chastre, F. Gudiol, and S. Harbarth, Management of methicillin-resistant Staphylococcus aureus infections, Clinical Microbiology and Infection, vol.15, issue.2, pp.125-136, 2009.
DOI : 10.1111/j.1469-0691.2009.02701.x

J. Garau, E. Bouza, J. Chastre, F. Gudiol, and S. Harbarth, Management of methicillin-resistant Staphylococcus aureus infections, Clinical Microbiology and Infection, vol.15, issue.2, pp.125-136, 2009.
DOI : 10.1111/j.1469-0691.2009.02701.x

J. Chastre, F. Blasi, R. Masterton, J. Rello, A. Torres et al., European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid, Clinical Microbiology and Infection, vol.20, pp.19-36, 2014.
DOI : 10.1111/1469-0691.12450

J. Fu, X. Ye, C. Chen, and S. Chen, The Efficacy and Safety of Linezolid and Glycopeptides in the Treatment of Staphylococcus aureus Infections, PLoS ONE, vol.14, issue.3, p.58240, 2013.
DOI : 10.1371/journal.pone.0058240.s002

A. Walkey, O. Donnell, M. Wiener, and R. , Linezolid vs Glycopeptide Antibiotics for the Treatment of Suspected Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia, Chest, vol.139, issue.5, pp.1148-1155, 2011.
DOI : 10.1378/chest.10-1556

P. Moise-broder, A. Forrest, M. Birmingham, and J. Schentag, Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections, Clinical Pharmacokinetics, vol.50, issue.6, pp.925-942, 2004.
DOI : 10.2165/00003088-200443130-00005

T. Lodise, G. Drusano, and E. Zasowski, Vancomycin Exposure in Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: How Much Is Enough?, Clinical Infectious Diseases, vol.59, issue.5, pp.666-675, 2014.
DOI : 10.1093/cid/ciu398

T. Lodise, N. Patel, B. Lomaestro, K. Rodvold, and G. Drusano, Relationship between Initial Vancomycin Concentration???Time Profile and Nephrotoxicity among Hospitalized Patients, Clinical Infectious Diseases, vol.49, issue.4, pp.507-514, 2009.
DOI : 10.1086/600884

S. Van-hal, D. Paterson, and T. Lodise, Systematic Review and Meta-Analysis of Vancomycin-Induced Nephrotoxicity Associated with Dosing Schedules That Maintain Troughs between 15 and 20 Milligrams per Liter, Antimicrobial Agents and Chemotherapy, vol.57, issue.2, pp.734-744, 2013.
DOI : 10.1128/AAC.01568-12

G. Wang, J. Hindler, K. Ward, and D. Bruckner, Increased Vancomycin MICs for Staphylococcus aureus Clinical Isolates from a University Hospital during a 5-Year Period, Journal of Clinical Microbiology, vol.44, issue.11, pp.3883-3886, 2006.
DOI : 10.1128/JCM.01388-06

D. Sievert, J. Rudrik, J. Patel, L. Mcdonald, M. Wilkins et al., Vancomycin-Resistant Staphylococcus aureus in the United States, 2002-2006, Clinical Infectious Diseases, vol.46, issue.5, pp.668-674, 2002.
DOI : 10.1086/527392

J. Pofelski, P. Pavese, and J. Brion, Staphylococcus aureus meningitis with intermediate sensitivity to glycopeptides. Therapeutic indications].PresseMédicale Paris Fr, pp.217-220, 1983.

S. Van-hal and D. Paterson, Systematic Review and Meta-Analysis of the Significance of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates, Antimicrobial Agents and Chemotherapy, vol.55, issue.1, pp.405-410, 2011.
DOI : 10.1128/AAC.01133-10

G. Sakoulas, P. Moise-broder, J. Schentag, A. Forrest, R. Moellering et al., Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia, Journal of Clinical Microbiology, vol.42, issue.6, pp.2398-2402, 2004.
DOI : 10.1128/JCM.42.6.2398-2402.2004

T. Lodise, J. Graves, and A. Evans, Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin, Antimicrobial Agents and Chemotherapy, vol.52, issue.9, pp.3315-3320, 2008.
DOI : 10.1128/AAC.00113-08

K. Estes and H. Derendorf, Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin, European Journal of Medical Research, vol.15, issue.12, pp.533-543, 2010.
DOI : 10.1186/2047-783X-15-12-533

Z. Li, R. Willke, and L. Pinto, Species Infections Treated with Linezolid or Vancomycin: A Randomized, Multicenter Trial, Pharmacotherapy, vol.14, issue.3, pp.263-274, 2001.
DOI : 10.1016/0002-9343(91)90181-V

A. Macgowan, Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections, Journal of Antimicrobial Chemotherapy, vol.51, issue.90002, pp.17-25, 2003.
DOI : 10.1093/jac/dkg248

R. Moellering, MRSA: the first half century, Journal of Antimicrobial Chemotherapy, vol.67, issue.1, pp.4-11, 2012.
DOI : 10.1093/jac/dkr437

R. Mendes, P. Hogan, J. Streit, R. Jones, and R. Flamm, Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity over 9 years (2004-12), Journal of Antimicrobial Chemotherapy, vol.69, issue.6, pp.1582-1588, 2014.
DOI : 10.1093/jac/dkt541

B. Gu, T. Kelesidis, S. Tsiodras, J. Hindler, and R. Humphries, The emerging problem of linezolid-resistant Staphylococcus, Journal of Antimicrobial Chemotherapy, vol.68, issue.1, pp.4-11, 2013.
DOI : 10.1093/jac/dks354

D. Chauhan and A. Mason, Factors affecting the uptake of new medicines in secondary care a literature review, Journal of Clinical Pharmacy and Therapeutics, vol.332, issue.4, pp.339-348, 2008.
DOI : 10.1111/j.1365-2710.2008.00925.x

R. Wunderink, J. Rello, S. Cammarata, R. Croos-dabrera, and M. Kollef, Linezolid vs Vancomycin*, Chest, vol.124, issue.5, pp.1789-1797, 2003.
DOI : 10.1016/S0012-3692(15)33412-7

R. Wunderink, M. Niederman, and M. Kollef, Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study, Clinical Infectious Diseases, vol.54, issue.5, pp.621-629, 2012.
DOI : 10.1093/cid/cir895

J. Conte, J. Golden, J. Kipps, and E. Zurlinden, Intrapulmonary Pharmacokinetics of Linezolid, Antimicrobial Agents and Chemotherapy, vol.46, issue.5, pp.1475-1480, 2002.
DOI : 10.1128/AAC.46.5.1475-1480.2002

P. Chavanet, The ZEPHyR study: A randomized comparison of linezolid and vancomycin for MRSA pneumonia, M??decine et Maladies Infectieuses, vol.43, issue.11-12, pp.451-455, 2013.
DOI : 10.1016/j.medmal.2013.09.011

J. Nemeth, G. Oesch, and S. Kuster, Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis, Journal of Antimicrobial Chemotherapy, vol.70, issue.2, pp.382-395, 2015.
DOI : 10.1093/jac/dku379

T. Lodise, P. Mckinnon, D. Levine, and M. Rybak, Impact of Empirical-Therapy Selection on Outcomes of Intravenous Drug Users with Infective Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureus, Antimicrobial Agents and Chemotherapy, vol.51, issue.10, pp.3731-3733, 2007.
DOI : 10.1128/AAC.00101-07

A. Shorr, M. Kunkel, and M. Kollef, Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies, Journal of Antimicrobial Chemotherapy, vol.56, issue.5, pp.923-929, 2005.
DOI : 10.1093/jac/dki355

T. Holland, C. Arnold, and V. Fowler, Bacteremia, JAMA, vol.312, issue.13, pp.1330-1341, 2014.
DOI : 10.1001/jama.2014.9743

M. Kollef, G. Sherman, S. Ward, and V. Fraser, Inadequate Antimicrobial Treatment of Infections, Chest, vol.115, issue.2, pp.462-474, 1999.
DOI : 10.1378/chest.115.2.462

R. Dellinger, M. Levy, and A. Rhodes, Surviving Sepsis Campaign, Critical Care Medicine, vol.41, issue.2, pp.165-228, 2013.
DOI : 10.1097/CCM.0b013e31827e83af

S. Beekmann, D. Gilbert, and P. Polgreen, Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey, Diagnostic Microbiology and Infectious Disease, vol.62, issue.4, pp.407-410, 2008.
DOI : 10.1016/j.diagmicrobio.2008.08.009

J. Conly, Controlling antibiotic resistance by quelling the epidemic of overuse and misuse of antibiotics, Can. Fam. Physician Médecin Fam. Can, vol.44, pp.1769-1773, 1998.

C. Adembri, S. Fallani, and M. Cassetta, Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion, International Journal of Antimicrobial Agents, vol.31, issue.2, pp.122-129, 2008.
DOI : 10.1016/j.ijantimicag.2007.09.009

M. Méan, P. Pavese, and J. Vittoz, Prospective assessment of fluoroquinolone use in a teaching hospital, European Journal of Clinical Microbiology & Infectious Diseases, vol.6, issue.12, pp.757-763, 2006.
DOI : 10.1007/s10096-006-0221-0

D. Patel, A. Shorr, and J. Chastre, Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus, Critical Care, vol.18, issue.4, p.157, 2014.
DOI : 10.1186/cc13996

C. Mullins, A. Kuznik, and F. Shaya, Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus, Clinical Therapeutics, vol.28, issue.8, pp.1184-1198, 2006.
DOI : 10.1016/j.clinthera.2006.08.016

M. Wilke, Multiresistant bacteria and current therapy - the economical side of the story, European Journal of Medical Research, vol.15, issue.12, pp.571-576, 2010.
DOI : 10.1016/j.diagmicrobio.2008.09.001

L. Saastamoinen and J. Verho, Register-based indicators for potentially inappropriate medication in high-cost patients with excessive polypharmacy, Pharmacoepidemiology and Drug Safety, vol.31, issue.Pt 1, 2015.
DOI : 10.1002/pds.3764

B. Heintz, J. Halilovic, and C. Christensen, Vancomycin-Resistant Enterococcal Urinary Tract Infections, Pharmacotherapy, vol.15, issue.47, pp.1136-1149, 2010.
DOI : 10.1056/NEJM199310283291808

N. Rao, B. Ziran, R. Hall, and E. Santa, Successful Treatment of Chronic Bone and Joint Infections with Oral Linezolid, Clinical Orthopaedics and Related Research, vol.427, pp.67-71, 2004.
DOI : 10.1097/01.blo.0000144860.11193.5e

M. Falagas, I. Siempos, P. Papagelopoulos, and K. Vardakas, Linezolid for the treatment of adults with bone and joint infections, International Journal of Antimicrobial Agents, vol.29, issue.3, pp.233-239, 2007.
DOI : 10.1016/j.ijantimicag.2006.08.030

G. Moran, A. Krishnadasan, and R. Gorwitz, Infections among Patients in the Emergency Department, New England Journal of Medicine, vol.355, issue.7, pp.666-674, 2006.
DOI : 10.1056/NEJMoa055356

S. Mcnicholas, A. Barber, G. Corbett-feeney, and M. Cormican, Linezolid audit: similarities and contrasts with published experience, Journal of Antimicrobial Chemotherapy, vol.57, issue.5, pp.1008-1009, 2006.
DOI : 10.1093/jac/dkl090

H. Ziglam, I. Elliott, V. Wilson, K. Hill, and D. Nathwani, Clinical audit of linezolid use in a large teaching hospital, Journal of Antimicrobial Chemotherapy, vol.56, issue.2, pp.423-426, 2005.
DOI : 10.1093/jac/dki185

S. Walker, L. Dresser, D. Becker, and A. Scalera, An assessment of linezolid utilization in selected canadian provinces. Can, J. Infect. Dis. Med. Microbiol. J. Can. Mal. Infect. Microbiol. Médicale AMMI Can, vol.17, pp.177-182, 2006.